Compare NVGS & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVGS | PSNL |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2013 | 2019 |
| Metric | NVGS | PSNL |
|---|---|---|
| Price | $23.19 | $16.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $21.50 | $12.20 |
| AVG Volume (30 Days) | 401.5K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | N/A | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | $13.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.08 | $4.96 |
| 52 Week High | $25.48 | $18.89 |
| Indicator | NVGS | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 51.63 |
| Support Level | $21.41 | $15.92 |
| Resistance Level | $24.36 | $16.39 |
| Average True Range (ATR) | 0.71 | 0.43 |
| MACD | -0.09 | -0.15 |
| Stochastic Oscillator | 27.11 | 15.68 |
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). The company plays a vital role in the globalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users, and commodity traders.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.